Wiregraph

Market coverage built from listed-company disclosures. Email [email protected] for any enquiries.

Copyright © 2025-2026 Wiregraph.com | Market data and charting by TradingView.com

BAVARIAN NORDIC

BAVA.CODK0015998017NASDAQ CopenhagenDKDKK
Stock price
BAVARIAN NORDIC
Loading chart...

Coverage

Latest articles

Bavarian Nordic board backs higher bid amid shareholder holdout
16 Oct 2025, 05:28BAVA.CONASDAQ Copenhagen

Bavarian Nordic's board of directors on Thursday reiterated its recommendation for shareholders to accept a takeover offer from a private equity consortium led by Nordic Capital and Permira.

Private equity raises Bavarian Nordic bid, faces shareholder test
15 Oct 2025, 15:59BAVA.CONASDAQ Copenhagen

A private equity consortium led by Nordic Capital and Permira has raised its takeover bid for Danish vaccine maker Bavarian Nordic to 250 Danish Krone per share from 233 Danish Krone.

Nordic Capital, Permira clear final hurdle for Bavarian Nordic takeover
9 Oct 2025, 12:24BAVA.CONASDAQ Copenhagen

A consortium led by private equity firms Nordic Capital and Permira has received the final regulatory approval needed for its proposed takeover of Danish vaccine maker Bavarian Nordic.

Bavarian Nordic's mpox vaccine shows strong results in children
7 Oct 2025, 14:59BAVA.CONASDAQ Copenhagen

Bavarian Nordic said Tuesday its mpox and smallpox vaccine produced a strong immune response and was well-tolerated in children aged 2 to 11 in a clinical study.

Bavarian Nordic posts strong results ahead of PE buyout
22 Aug 2025, 05:38BAVA.CONASDAQ Copenhagen

Danish vaccine maker Bavarian Nordic on Friday reported a 33% rise in first-half revenue, posting strong results as it prepares for a takeover by a private equity consortium.

Bavarian Nordic agrees to DKK 19 billion takeover offer
6 Aug 2025, 20:30BAVA.CONASDAQ Copenhagen

A consortium led by private equity firms Nordic Capital and Permira has agreed to acquire Danish vaccine maker Bavarian Nordic in an all-cash deal valuing the company at approximately 19 billion Danish Krone.

  • Previous
  • 1
  • 2

Filings

Recent filings

FilingDate
Bavarian Nordic Publishes Annual Report 20245 Mar 2025
Bavarian Nordic Receives Marketing Authorization in Europe for Chikungunya Vaccine for Persons Aged 12 and Older28 Feb 2025
Bavarian Nordic Receives U.S. FDA Approval of Chikungunya Vaccine for Persons Aged 12 and Older14 Feb 2025
Bavarian Nordic Reports Preliminary 2024 Financial Results in Line with Upgraded Guidance and Guides for 20253 Feb 2025
Bavarian Nordic - Completion of Share Buy-Back Program31 Jan 2025
Bavarian Nordic Receives Positive CHMP Opinion for Chikungunya Vaccine for Persons Aged 12 and Older31 Jan 2025
Bavarian Nordic - Transactions in Connection with Share Buy-Back Program 27 Jan 2025
Bavarian Nordic - Transactions in Connection with Share Buy-Back Program 20 Jan 2025
Bavarian Nordic Launches Planned Share Buy-Back Program of DKK 150 Million9 Jan 2025
New Incentive Program Established for Members of Executive Management and Selected Employees in Bavarian Nordic 13 Dec 2024
Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such 13 Dec 2024
Bavarian Nordic to Launch DKK 150 Million Share Buy-back Program11 Dec 2024
  • Previous
  • 1
  • More pages
  • 3
Search
Company
BAVARIAN NORDIC
BAVA.CONASDAQ Copenhagen
Website: Unavailable
Coverage
14
  • 3
  • Next
  • 4
  • 5
  • More pages
  • 78
  • Next
  • Filings
    927